Search Results - "Klingemann, H.G"

Wharton's jelly derived mesenchymal stem cells: regenerative medicine beyond umbilical cord blood by Taghizadeh, R.R, Pollok, K.E, Betancur, M, Boissel, L, Cetrulo, K.J, Marino, T, Wolfberg, A, Klingemann, H.G, Cetrulo, C.L

Get full text

CAR-MEDIATED TARGETING OF NK CELLS OVERCOMES TUMOR IMMUNE ESCAPE CAUSED BY ICAM-1 DOWNREGULATION by Eitler, J., Rackwitz, W., Wotschel, N., Gudipati, V., Shankar, N. Murali, Sidorenkova, A., Huppa, J.B., Montero, P.O., Opitz, C., Künzel, S.R., Michen, S., Temme, A., Loureiro, L., Feldmann, A., Bachmann, M., Boissel, L., Klingemann, H.G., Wels, W.S., Tonn, T.

“…The antitumor activity of natural killer (NK) cells can be enhanced by specific targeting with therapeutic antibodies that trigger antibody-dependent…”
Get full text

High-Dose Cyclophosphamide, Carmustine (BCNU), and Etoposide (VP16-213) With or Without Cisplatin (CBV ± P) and Autologous Transplantation for Patients With Hodgkin's Disease Who Fail to Enter a Complete Remission After Combination Chemotherapy by Reece, D.E., Barnett, M.J., Shepherd, J.D., Hogge, D.E., Klasa, R.J., Nantel, S.H., Sutherland, H.J., Klingemann, H.G., Fairey, R.N., Voss, N.J., Connors, J.M., O'Reilly, S.E., Spinelli, J.J., Phillips, G.L

“…Patients with Hodgkin's disease (HD) who fail to enter a complete remission after an initial course of combination chemotherapy are usually considered to have…”
Get full text

High dose mitoxantrone and melphalan followed by autologous stem cell transplantation for lymphoid malignancies by Chan, G.W., Sprague, K.A., Klein, A.K., Klingemann, H.G.

Get full text

Allografting for indolent lymphoid neoplasms by Toze, C. L., Shepherd, J. D., Connors, J. M., Voss, N. J., Gascoyne, R. D., Hogge, D. E., Klingemann, H. G., Nantel, S. H., Nevill, T. J., Phillips, G. L., Reece, D. E., Sutherland, H. J., Conneally, E. A., Barnett, M. J.

“…Background: Allogeneic bone marrow transplantation (BMT) has been used in patients with low-grade lymphoma (LGL) and chronic lymphocytic leukemia (CLL) with…”
Get full text

Detection of Breakpoint Cluster Region-Negative and Nonclonal Hematopoiesis In Vitro and In Vivo After Transplantation of Cells Selected in Cultures of Chronic Myeloid Leukemia Marrow by Turhan, A.G., Humphries, R.K., Eaves, C.J., Barnett, M.J., Phillips, G.L., Kalousek, D.K., Klingemann, H.G., Lansdorp, P.L., Reece, D.E., Shepherd, J.D., Eaves, A.C.

“…Philadelphia (Ph1) chromosome-positive clonogenic progenitors usually disappear within 4 to 6 weeks in long-term cultures established from the marrow of…”
Get full text